More Articles

The role of generic medicines in Europe Reports | Posted 11/06/2010

The role of generic medicines has been to provide essential medicines that are both high quality and affordable throughout the EU. They have enabled increased access to medicines for patients and p...

The rising cost of health care in Europe Reports | Posted 11/06/2010

The ageing population and lifestyle changes bring an increased burden on health care and consequently an increase in costs. This growing cost of health care is unavoidable, and drug expenditure is...

Is the quality of generic medicines under pressure? Generics/News | Posted 11/06/2010

“You get what you pay for” runs the old adage, and concerns are being expressed that a number of firms providing clopidogrel in Europe have all sourced the active ingredient from the same Indian fi...

EGA welcomes MEPs decisions on falsified medicines and pharmacovigilance reports Pharma News | Posted 11/06/2010

On 27 April 2010, ENVI (The Committee on the Environment, Public Health and Food Safety) of the European Parliament voted to adopt reports on both falsified medicines and pharmacovigilance. The mea...

FDA rejects second citizen petition for Teva’s glatiramer acetate drug Pharma News | Posted 04/06/2010

Teva Pharmaceutical Industries’ glatiramer acetate drug (Copaxone) is indicated for reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.

Spanish government urged to increase generics volume Policies & Legislation | Posted 04/06/2010

In response to recent stringent price-cutting measures introduced in Spain, the Director General of the European Generic Medicines Association (EGA), Mr Greg Perry, has written to the Spanish Minis...

Spanish government introduces harsh generic price cuts Policies & Legislation | Posted 04/06/2010

There has been a sustained slowdown in the Spanish economy since 2008. This has been aggravated by the major international financial crisis, resulting in a decrease in the Spanish Gross Domestic Pr...

Phase III study of a new biosimilar filgrastim product (Zarzio) published Biosimilars/Research | Posted 04/06/2010

A biosimilar recombinant human granulocyte colony-stimulating factor (filgrastim) (rhG-CSF), Zarzio (Sandoz GmbH), was evaluated in healthy volunteers in four phase I studies and in neutropenic pat...